Trials / Active Not Recruiting
Active Not RecruitingNCT05692492
A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-blind, Placebo-controlled Phase 2b Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research is to evaluate the efficacy and the safety of two doses of ZSP1601 for 48 weeks versus placebo in adult NASH patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZSP1601 | 50mg BID |
| DRUG | ZSP1601 | 100mg BID |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2023-06-03
- Primary completion
- 2026-06-16
- Completion
- 2026-12-16
- First posted
- 2023-01-20
- Last updated
- 2025-03-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05692492. Inclusion in this directory is not an endorsement.